New BioTrends Report Highlights the Current Treatment Approaches and Major Drivers of Prescribing Choice for Noninfectious Uveit

EXTON, Pa., Aug. 24 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Noninfectious Uveitis. This report, based on feedback gathered in an on-line survey completed by 72 retinal specialists in June/July 2010, addresses the medical management of noninfectious uveitis (anterior, intermediate, posterior and panuveitis) and referral/co-management patterns between retinal specialists and other specialties.

The study focuses on the use of corticosteroids (topical, systemic, periocular, intravitreal injections and implants, and intravenous) and steroid-sparing drug classes (immunosuppressants, alkylating agents, and biologics) by retinal specialists for the treatment of noninfectious uveitis. In addition to uncovering the attributes that are most important to retinal specialists when choosing therapies to treat non-infectious uveitis, the report delves into physician attitudes and perceptions toward these drug classes, overall advantages and disadvantages, barriers to growth and expected future use of specific products within the drug classes. Promotional activity for Bausch & Lomb's Retisert and Alcon's Durezol and Triesence is also assessed.

Respondents were queried about their awareness of and interest in products in development for noninfectious uveitis including Lux Biosciences' Luveniq, Celgene's apremilast, Eyegate Pharma's EGP-457 and Novartis' AIN-457. Retinal specialists feel that products that are easily managed by general ophthalmologists and those that have the potential for long-term, drug-free remission would go the farthest in filling the greatest unmet needs in the treatment of noninfectious uveitis.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or BioTrends Research Group, Inc. is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

BioTrends Research Group, Inc.

Sharon Funk


[email protected]

Decision Resources, Inc.

Christopher Comfort


[email protected]

SOURCE BioTrends Research Group, Inc.